(5E)-5-[(2-Hydroxy-3-methoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione

Catalog No.: 
ACGORE861
CAS No.: 
312944-88-0
Molecular Formula: 
C11H9NO4S
Molecular Weight: 
251.26
(5E)-5-[(2-Hydroxy-3-methoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg90%$183.00InquiryInquiry
1g90%$566.00InquiryInquiry
5g90%$2802.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(5E)-5-[(2-Hydroxy-3-methoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione
IUPAC Name(E)-5-(2-hydroxy-3-methoxybenzylidene)thiazolidine-2,4-dione
MDL No.MFCD00640655
Molecular FormulaC11H9NO4S
Molecular Weight251.26
SMILESO=C(NC/1=O)SC1=C\C2=CC=CC(OC)=C2O
InChI KeyYWULELJUDXQYSW-VMPITWQZSA-N
Synonym5-[(E)-(2-HYDROXY-3-METHOXYPHENYL)METHYLIDENE]-1,3-THIAZOLANE-2,4-DIONE;(5E)-5-[(2-hydroxy-3-methoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione;5-[(2-Hydroxy-3-methoxyphenyl)methylene]-2,4-thiazolidinedione;2,4-Thiazolidinedione, 5-[(2-hydroxy-3-methoxyphenyl)methylene]-
CAS No.312944-88-0

Synthetic Route by SureRoute

1. ACGORE861 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTONS619 route compound structure diagram
    ACTONS619148-53-8In Stock
  2. Plus
  3. ACOFNI502 route compound structure diagram
    ACOFNI5022295-31-0In Stock
  4. Then
  5. ACGORE861 route product structure diagram
    ACGORE861312944-88-0
Inquiry

2. ACGORE861 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGORE861 route product structure diagram
    ACGORE861312944-88-0
Inquiry

3. ACGORE861 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGORE861 route product structure diagram
    ACGORE861312944-88-0
Inquiry

Comments (0)